Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene ...
Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback